Thomas P R, Lindblad A S, Stablein D M, Knowlton A H, Bruckner H W, Childs D S, Mittelman A
Cancer. 1986 Mar 15;57(6):1130-4. doi: 10.1002/1097-0142(19860315)57:6<1130::aid-cncr2820570612>3.0.co;2-l.
The Gastrointestinal Tumor Study Group's (GITSG) adjuvant rectal carcinoma study compared four postoperative treatment regimens: (1) control (no adjuvant therapy); (2) chemotherapy alone consisting of pulses of 5-fluorouracil and methyl CCNU for 18 months; (3) pelvic and perineal radiotherapy using parallel opposed fields with 4000 rad in 4.5 to 5 weeks or 4800 rad in 5 to 5.5 weeks; and (4) a combination of both modalities. The results of this study are published elsewhere and show a significantly reduced recurrence rate and prolonged disease-free survival time for the combined modality arm compared with the no therapy arm. Severe toxicity in the combined therapy arm was significantly worse (P less than 0.001) than in either single modality arm. Most of the differences in toxicity experienced between the three regimens involved diarrhea, thrombocytopenia, and leukopenia. Analysis of all parameters of radiotherapy quality assurance data was not significantly associated with toxicity. Radiation enteritis was noted in 5 patients of 96 (5.2%) in the two arms containing irradiation. All five required laparotomy. The two enteritis fatalities occurred late at 605 and 1000 days after start of combined modality treatment, respectively. One other patient on the chemotherapy arm died of acute nonlymphocytic leukemia. The authors conclude that combined radiotherapy and chemotherapy, although significantly more effective in reducing recurrence than no therapy, is significantly more toxic than single-modality therapy in many parameters, although most of the toxicity is transient and therefore not limiting. Late complications, which are less reversible and therefore much more important than early reactions, and radiation enteritis in this study were relatively uncommon. This schedule of combined modality therapy is not only effective but appears to have tolerable toxicity, because of the relative lack of late effects.
胃肠道肿瘤研究组(GITSG)的直肠癌辅助治疗研究比较了四种术后治疗方案:(1)对照组(无辅助治疗);(2)单纯化疗,采用5-氟尿嘧啶和甲基环己亚硝脲脉冲给药,持续18个月;(3)盆腔和会阴放疗,使用平行相对野,在4.5至5周内给予4000拉德或在5至5.5周内给予4800拉德;(4)两种治疗方式联合使用。这项研究的结果已在其他地方发表,结果显示,与未治疗组相比,联合治疗组的复发率显著降低,无病生存期延长。联合治疗组的严重毒性明显比单一治疗组更严重(P小于0.001)。三种治疗方案在毒性方面的大多数差异涉及腹泻、血小板减少和白细胞减少。放疗质量保证数据的所有参数分析与毒性无显著相关性。在接受照射的两组中的96名患者中有5名(5.2%)出现放射性肠炎。所有5例均需剖腹手术。两例放射性肠炎死亡分别发生在联合治疗开始后的605天和1000天,时间较晚。化疗组的另一名患者死于急性非淋巴细胞白血病。作者得出结论,联合放疗和化疗虽然在降低复发方面比不治疗显著更有效,但在许多参数上比单一治疗毒性显著更大,不过大多数毒性是短暂的,因此并不构成限制。晚期并发症较难逆转,因此比早期反应重要得多,而本研究中的放射性肠炎相对不常见。这种联合治疗方案不仅有效,而且由于相对缺乏晚期效应,似乎具有可耐受的毒性。